Journal
AMERICAN JOURNAL OF PERINATOLOGY
Volume 37, Issue 4, Pages 421-429Publisher
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0039-1681014
Keywords
respiratory syncytial virus; infants; palivizumab; immunoprophylaxis; hospitalizations
Categories
Funding
- AstraZeneca
Ask authors/readers for more resources
Objective The SENTINEL1 observational study characterized confirmed respiratory syncytial virus hospitalizations (RSVH) among U.S. preterm infants born at 29 to 35 weeks' gestational age (wGA) not receiving respiratory syncytial virus (RSV) immunoprophylaxis (IP) during the 2014 to 2015 and 2015 to 2016 RSV seasons. Study Design All laboratory-confirmed RSVH at participating sites during the 2014 to 2015 and 2015 to 2016 RSV seasons (October 1-April 30) lasting >= 24 hours among preterm infants 29 to 35 wGA and aged Results Results were similar across the two seasons. Among infants with community-acquired RSVH ( N = 1,378), 45% were admitted to the intensive care unit (ICU) and 19% required invasive mechanical ventilation (IMV). There were two deaths. Infants aged <6 months accounted for 78% of RSVH observed, 84% of ICU admissions, and 91% requiring IMV. Among infants who were discharged from their birth hospitalization during the RSV season, 82% of RSVH occurred within 60 days of birth hospitalization discharge. Conclusion Among U.S. preterm infants 29 to 35 wGA not receiving RSV IP, RSVH are often severe with almost one-half requiring ICU admission and about one in five needing IMV.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available